JP2006506466A - チオモリブデン酸類似物及びそれらの使用 - Google Patents

チオモリブデン酸類似物及びそれらの使用 Download PDF

Info

Publication number
JP2006506466A
JP2006506466A JP2005505545A JP2005505545A JP2006506466A JP 2006506466 A JP2006506466 A JP 2006506466A JP 2005505545 A JP2005505545 A JP 2005505545A JP 2005505545 A JP2005505545 A JP 2005505545A JP 2006506466 A JP2006506466 A JP 2006506466A
Authority
JP
Japan
Prior art keywords
substituted
patient
compound
compound according
alkyleno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005505545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506466A5 (enExample
Inventor
ジェイ． テルナンスキー，ロバート
マザー，アンドリュー
エル． グラッドストーン，パトリシア
ククバニス，ディミトリ
エイミー エル． アラン
エム． オヘア，ショーン
エル．ピー． プライス，メリッサ
ロバート ピリエ−シェパード，スティーブン
ドネイト，フェルナンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/202,346 external-priority patent/US20040019043A1/en
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of JP2006506466A publication Critical patent/JP2006506466A/ja
Publication of JP2006506466A5 publication Critical patent/JP2006506466A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/20—Quaternary compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F11/00—Compounds containing elements of Groups 6 or 16 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/64—Quaternary ammonium compounds having quaternised nitrogen atoms bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/037—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements with quaternary ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2005505545A 2002-07-23 2003-07-22 チオモリブデン酸類似物及びそれらの使用 Pending JP2006506466A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/202,346 US20040019043A1 (en) 2002-07-23 2002-07-23 Thiomolybdate analogues and uses thereof
US43474202P 2002-12-18 2002-12-18
US43695803A 2003-05-12 2003-05-12
US10/447,585 US7189865B2 (en) 2002-07-23 2003-05-28 Thiomolybdate analogues and uses thereof
PCT/US2003/023031 WO2004009034A2 (en) 2002-07-23 2003-07-22 Thiomolybdate analogues and uses thereof

Publications (2)

Publication Number Publication Date
JP2006506466A true JP2006506466A (ja) 2006-02-23
JP2006506466A5 JP2006506466A5 (enExample) 2006-09-14

Family

ID=30773643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005505545A Pending JP2006506466A (ja) 2002-07-23 2003-07-22 チオモリブデン酸類似物及びそれらの使用

Country Status (19)

Country Link
US (1) US7189865B2 (enExample)
EP (1) EP1556029B1 (enExample)
JP (1) JP2006506466A (enExample)
KR (1) KR20050053596A (enExample)
CN (1) CN100531732C (enExample)
AU (1) AU2003256704A1 (enExample)
BR (1) BR0312851A (enExample)
CA (1) CA2493127A1 (enExample)
DK (1) DK1556029T3 (enExample)
EA (1) EA200500250A1 (enExample)
ES (1) ES2448800T3 (enExample)
HR (1) HRP20050174A2 (enExample)
IL (1) IL166448A0 (enExample)
MX (1) MXPA05000870A (enExample)
NO (1) NO20050917L (enExample)
PL (1) PL374821A1 (enExample)
PT (1) PT1556029E (enExample)
SI (1) SI1556029T1 (enExample)
WO (1) WO2004009034A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008106006A (ja) * 2006-10-26 2008-05-08 Univ Nihon 筋萎縮性側索硬化症治療薬
WO2015083585A1 (ja) * 2013-12-05 2015-06-11 デクセリアルズ株式会社 化合物、熱硬化性樹脂組成物、及び熱硬化性シート
JP2021505655A (ja) * 2017-12-04 2021-02-18 アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2021512948A (ja) * 2018-02-06 2021-05-20 アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー ビス−コリンテトラチオモリブデン酸塩の結晶性粒子
JP2021513970A (ja) * 2018-02-15 2021-06-03 アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー ビス−コリンテトラチオモリブデートの製造方法
JP2022517611A (ja) * 2019-01-14 2022-03-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド テトラチオモリブデン酸アンモニウムの調製方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018392A1 (en) * 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
EP1177197B1 (en) * 1999-04-30 2006-08-09 Cellgate, Inc. Polyamines and their use in therapy
WO2002038105A2 (en) * 2000-11-08 2002-05-16 Slil Biomedical Corporation Novel polyamine analog-amino acid conjugates useful as anticancer agents
WO2000066175A2 (en) * 1999-04-30 2000-11-09 Slil Biomedical Corporation Conjugates as therapies for cancer and prostate diseases
JP2005504060A (ja) * 2001-08-24 2005-02-10 メイン・メデイカル・センター・リサーチ・インステイテユート 銅依存性の非伝統的前炎症性サイトカイン輸送およびそれに関連する方法、組成物およびキット
AU2002340224B2 (en) * 2001-10-16 2008-11-27 Progen Pharmaceuticals, Inc Oligoamine compounds and derivatives thereof for cancer therapy
EP1487431B1 (en) * 2002-03-08 2012-05-02 PhilERA New Zealand Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US6855340B2 (en) * 2002-05-24 2005-02-15 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
MXPA05000875A (es) * 2002-07-23 2005-09-30 Univ Michigan Tetratiomolibdato de tetrapropilamonio y compuestos relacionados para terapias anti-angiogenicas.
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
EP1633310A4 (en) * 2003-05-27 2006-10-18 Attenuon Llc THIOWOLFRAM ANALOGUE AND ITS USES
EP1729784A1 (en) * 2004-02-23 2006-12-13 Attenuon, LLC Formulations of thiomolybdate or thiotungstate compounds and uses thereof
WO2005083107A2 (en) * 2004-02-24 2005-09-09 Attenuon Llp Inhibition of superoxide dismutase by tetrathiomolybdate: identification of new anti-angiogenic and antitumor agents
WO2006027705A2 (en) 2004-07-19 2006-03-16 Protemix Corporation Limited Synthesis of triethylenetetramines
EP2117315A1 (en) * 2007-02-21 2009-11-18 SSV Therapeutics, Inc. Adamantanamines and neramexane salts of thiomolybdic and thiotungstic acids
PL381862A1 (pl) 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia
US20090028800A1 (en) * 2007-07-27 2009-01-29 Peeples William H Method of Treating Postpartum Depression and Aggression
US20110028513A1 (en) * 2008-03-31 2011-02-03 Lang Zhuo Method for treating neurological disorders with imidazolium and imidazolinium compounds
KR102650426B1 (ko) * 2016-02-23 2024-03-21 반더빌트 케미칼스, 엘엘씨 윤활 첨가제로서 4차 암모늄 황 함유 2핵 몰리브데이트 염
US11419832B2 (en) 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
JP2023549037A (ja) 2020-10-07 2023-11-22 シーティーアイ バスキュラー アーゲー 生物活性型に変換可能なデバイスおよび関連する方法
US20240100088A1 (en) * 2021-01-31 2024-03-28 Alexion Pharmaceuticals, Inc. Novel formulation for treating copper metabolism-associated diseases or disorders
WO2023086873A1 (en) * 2021-11-10 2023-05-19 Reverspah Llc Methods and compositions for treating cancer
CN114042083B (zh) * 2021-12-06 2022-08-30 湖南师范大学 四硫代钼酸盐的增肌及治疗应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909541A (en) 1955-01-07 1959-10-20 Inst Francais Du Petrole Nitrogenous thiomolybdates
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4400282A (en) 1980-12-05 1983-08-23 Gulf Research & Development Company Lubricating oils containing quaternary ammonium thiomolybdates
US4343746A (en) 1980-12-10 1982-08-10 Gulf Research & Development Company Quaternary ammonium thiomolybdates
US4430443A (en) * 1982-07-20 1984-02-07 Exxon Research And Engineering Co. Supported carbon-containing molybdenum and tungsten sulfide catalysts, their preparation and use
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
ES2177771T3 (es) 1995-03-14 2002-12-16 Siemens Ag Dispositivo atomizador ultrasonico con unidad desmontable de dosificacion de precision.
ATE186222T1 (de) 1995-03-14 1999-11-15 Siemens Ag Ultraschallzerstäuber mit abnehmbarer präzisionsdosiereinheit
US5954047A (en) 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
WO1999020374A1 (en) 1997-10-17 1999-04-29 Ebara Corporation Method and apparatus for processing exhaust gas of semiconductor fabrication
IL141550A0 (en) * 1998-09-04 2002-03-10 Univ Michigan Methods and compositions for the prevention or treatment of cancer
CN1262226A (zh) 1999-12-03 2000-08-09 中国科学院兰州化学物理研究所 硫代钼酸盐及其制备方法和用途
US6855340B2 (en) * 2002-05-24 2005-02-15 Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
MXPA05000875A (es) * 2002-07-23 2005-09-30 Univ Michigan Tetratiomolibdato de tetrapropilamonio y compuestos relacionados para terapias anti-angiogenicas.

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008106006A (ja) * 2006-10-26 2008-05-08 Univ Nihon 筋萎縮性側索硬化症治療薬
WO2015083585A1 (ja) * 2013-12-05 2015-06-11 デクセリアルズ株式会社 化合物、熱硬化性樹脂組成物、及び熱硬化性シート
JP2015108091A (ja) * 2013-12-05 2015-06-11 デクセリアルズ株式会社 化合物、熱硬化性樹脂組成物、及び熱硬化性シート
JP2021505655A (ja) * 2017-12-04 2021-02-18 アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー ウィルソン病を治療するためのビスコリンテトラチオモリブデート
JP2021512948A (ja) * 2018-02-06 2021-05-20 アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー ビス−コリンテトラチオモリブデン酸塩の結晶性粒子
JP2021513970A (ja) * 2018-02-15 2021-06-03 アレクシオン・ファーマ・インターナショナル・オペレーションズ・アンリミテッド・カンパニー ビス−コリンテトラチオモリブデートの製造方法
JP7394773B2 (ja) 2018-02-15 2023-12-08 アレクシオン・ファーマ・インターナショナル・オペレーションズ・リミテッド ビス－コリンテトラチオモリブデートの製造方法
JP2022517611A (ja) * 2019-01-14 2022-03-09 アレクシオン ファーマシューティカルズ， インコーポレイテッド テトラチオモリブデン酸アンモニウムの調製方法
JP7507163B2 (ja) 2019-01-14 2024-06-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド テトラチオモリブデン酸アンモニウムの調製方法

Also Published As

Publication number Publication date
US7189865B2 (en) 2007-03-13
SI1556029T1 (sl) 2014-06-30
EA200500250A1 (ru) 2005-12-29
DK1556029T3 (en) 2014-03-10
EP1556029A2 (en) 2005-07-27
EP1556029B1 (en) 2013-11-27
WO2004009034A2 (en) 2004-01-29
WO2004009034A3 (en) 2004-09-10
CN100531732C (zh) 2009-08-26
HRP20050174A2 (en) 2005-10-31
CN1684678A (zh) 2005-10-19
AU2003256704A1 (en) 2004-02-09
PT1556029E (pt) 2014-03-04
KR20050053596A (ko) 2005-06-08
CA2493127A1 (en) 2004-01-29
EP1556029A4 (en) 2008-06-25
ES2448800T3 (es) 2014-03-17
NO20050917L (no) 2005-04-20
PL374821A1 (en) 2005-10-31
US20040019087A1 (en) 2004-01-29
IL166448A0 (en) 2006-01-15
MXPA05000870A (es) 2005-08-29
BR0312851A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
JP2006506466A (ja) チオモリブデン酸類似物及びそれらの使用
US20110151022A1 (en) Thiotungstate analogues and uses thereof
CA3017645C (en) 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
JP2016516812A (ja) アミドピリジンオール誘導体またはその薬剤学的に許容可能な塩、及びそれを有効成分として含有する薬学組成物
CN102653522B (zh) ω-羧基取代的二苯基硫脲类化合物及其制备方法和用途
EP3641760A1 (en) Novel antibacterial compounds and methods of making and using same
US20170157135A1 (en) Functionalised and substituted indoles as anti-cancer agents
US20040019043A1 (en) Thiomolybdate analogues and uses thereof
CN118620019A (zh) 一种yap降解剂及其制备方法和药学上的应用
CN114920728B (zh) 一种甲异靛衍生物及其制备方法与应用
AU2006210627B2 (en) Acid addition salts of Ac-PHSCN-NH2
TW200538107A (en) Thiotungstate analogues and uses thereof
WO2026006488A1 (en) Angiogenesis inhibitors and uses thereof
WO2025176750A1 (en) Dual targeting in a new class of active ingredients
CN114853751A (zh) 一组吩噻嗪类衍生物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060724

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20091209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091222

A256 Written notification of co-pending application filed on the same date by different applicants

Free format text: JAPANESE INTERMEDIATE CODE: A2516

Effective date: 20091222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100329

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100817